+ 0.60
+ 0.4%

Respira Technologies Closes $2.25M Seed Funding Round

January 13, 2020 1:28 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Respira Technologies Closes $2.25M Seed Funding Round

Respira Technologies, a platform biotechnology company offering a “no heat” pod-based inhalation system for nicotine, THC or CBD — WAVE –announced last week it had closed a $2.25 million seed-funding round led by Evolution Venture Partners and Poseidon Asset Management.

The company says its WAVE system is the only vaping device in the world that requires no heating elements to successfully aerosolize the liquid suspension and, therefore, produces zero carcinogens. The team says it’s also working on facilitating the inhalation of a broad range of pharmaceuticals.

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

“When it comes to product safety, it's actually about materials and methods," founder and CEO Mario Danek told Benzinga. "Everyone is constantly talking about materials, such as the Vitamin E acetate additives found in illicit vapes… but nobody is talking methods.”

He added, “when it comes to establishing product safety standards, the method of delivery matters just as much as quality and control procedures. It is an inescapable fact that the interaction between heating elements and the e-liquid in these vapes creates toxic byproducts which are then unwittingly inhaled by consumers, resulting in potential harm from inhalation exposure.”

Respira’s patent-pending technology suite and ongoing efforts seek to eliminate consumer and public exposure to all known harmful and potentially harmful substances, like nicotine and tobacco.

The system utilizes proprietary ultrasonic oscillation and energy transfer, along with other undisclosed features, for a practical, safe, enjoyable plume, of aerosol or “vapor.” The e-liquid cartridges are filled with biomedical-grade formulas that undergo Liposomal nanoemulsion techniques for optimal drug delivery, deposition and diffusion.

Related Articles

The Blinc Group Closes $1.5M Pre-Series A Bridge Round

Vaporizer technologies company The Blinc Group, Inc. announced Thursday the closing of a pre-Series A bridge financing of $1.5 million. The round was led by Equitas Partners Fund, WGD Capital, LP, and 7thirty Capital. CEO and co-founder Arnaud Dumas de Rauly says proceeds from the raise will be used to: read more

Vext Science Upsizes Bought Deal Public Offering To Raise $18M

Vertically integrated CBD company Vext Science Inc. (CSE: VEXT) (OTCQX: VEXTF) is poised to raise $18 million through a bought deal offering of its units. read more

RWB Completes Cash Payments For $35M Platinum Vape Acquisition

Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) has wrapped up its purchase of Platinum Vape. read more

Subversive Capital Acquisition Corp. Upsizes Offering From $36.5M To $63M

Subversive Capital Acquisition Corp. (OTCQX: SBVCF) announced Thursday it has upsized a previously announced private placement. read more

Columbia Care To Raise CA$130M In Deal With Canaccord Genuity

Columbia Care Inc. (OTCQX: CCHWF) intends to raise CA$130 million ($102.5 million) through a bought deal offering. read more